"As the first market in Asia, we are pleased to bring to Hong Kong this medication for migraine, as we understand how migraine can adversely impact patients' quality of life including work, school, leisure and social activities," said Krishnamoorthy Sundaresan, General Manager, Pfizer Hong Kong and Macau. "At Pfizer, we remain committed to bringing breakthroughs that change patients' lives, ensuring equitable and affordable access to advance medicines and vaccines."

Results from the Phase 3 study published in Lancet demonstrated that a single dose of Rimegepant provided superior reduction in pain and associated symptoms of migraine at two hours compared to placebo.^[1] Another study, also published in Lancet, demonstrated that Rimegepant, when taken every other day, provided superior reduction in the number of days per month with migraine in Weeks 9 –12 of the 12-week administration period when compared to placebo.^[2]

Rimegepant is launched in over 39 markets to date^[7], including in the United States, and in the European Union and the United Kingdom. Additional regulatory applications are under review around the world.  

Rimegepant is now available in Hong Kong. Healthcare professionals will be able to decide how they want to prescribe Rimegepant based on the locally approved dosing.